Novel translational model of resolving inflammation triggered by UV-killed E. coli by Motwani, MP et al.
Novel translational model of resolving inflammation triggered
by UV-killed E. coli
Madhur P Motwani,1 Julia D Flint,1 Roel PH De Maeyer,1 James N Fullerton,1 Andrew M Smith,2
Daniel JB Marks3 and Derek W Gilroy1*
1 Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, 5 University Street, University College London, London WC1E 6JF,
UK
2Microbial Diseases, Eastman Dental Institute, University College London, London WC1X 8LD, UK
3 Centre for Molecular Medicine, Division of Medicine, 5 University Street, University College London, London WC1E 6JF, UK
*Correspondence to: DerekWGilroy, Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, 5 University Street, University
College London, LondonWC1E6JF,UK. email: d.gilroy@ucl.ac.uk
Abstract
Whilst numerous studies investigating the aetiology of inflammatory diseases have been performed in rodents,
the applicability of these data to human pathophysiology is frequently debated. Regardless of the strengths
and weaknesses of rodent models in biomedical research, there is a need to develop models of experimental
inflammation in humans. Here, we describe a self-resolving acute inflammatory response triggered by the
intradermal injection of UV-killed Escherichia coli into the forearm of healthy volunteers. Cells and exudates
were harvested from onset to resolution by applying negative pressure over the inflamed site. Onset was char-
acterized by high blood flow, neutrophilia and peak levels of pro-inflammatory cytokines, whilst resolution
showed a decline in blood blow, reduction in neutrophils, increase in monocytes/macrophages and waning of
classic pro-inflammatory cytokine levels. An anti-inflammatory effect, defined as suppression of onset phase
events, was demonstrated by administering naproxen, a conventional non-steroidal anti-inflammatory drug. In
summary, this model of resolving acute inflammation is minimally invasive, highly tractable and allows simul-
taneous investigation of the vascular response, cellular trafficking and chemical mediator profile of onset and
resolution phases of acute inflammation in humans. It can serve as a translational platform to provide mecha-
nistic insights and to test the clinical efficacy of novel anti-inflammatory and pro-resolving drugs, and also as
a tool in patients to explore inherent defects in resolution pathways.
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Introduction
Mounting a robust inflammatory response to infection
or injury is central to host defence and well-being.
However, persistence of this response can lead to a
chronic inflammatory state, believed to contribute to
the pathology of many diseases in the western world
such as cancer, atherosclerosis and rheumatoid arthri-
tis [1]. Thus, understanding the factors that control
the resolution of the inflammatory response may
offer a novel therapeutic approach to treat chronic
inflammatory disorders [2]. Over the years many
rodent models of acute and chronic inflammation
have been developed in order to mimic various dis-
ease processes [3]. Indeed, much of the current anti-
inflammatory pharmacopoeia has been derived from
these models, and is largely based on inhibiting fac-
tors that drive the acute inflammatory response, such
as prostaglandins (non-steroidal anti-inflammatory
drugs) and TNF-a (biological therapies) [4].
Whilst animal models of inflammation have gener-
ated invaluable information on cell trafficking and cell
clearance, as well as the receptors and soluble mediators
that control these processes, their relevance to human
physiology and pathology has been questioned. This
disparity was exemplified by a recent report showing
that, although acute inflammatory stimuli such as
trauma, burns and endotoxin result in highly stereotyped
genomic responses in humans, equivalent responses in
mouse models were not comparable [5]. Whilst
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controversial [6,7], this has led to a call for ‘higher pri-
ority for translational medical research to focus on the
more complex human conditions rather than relying on
mouse models to study human inflammatory diseases
[5]. However, studying fundamental resolution biology
in patients is challenging due to disease heterogeneity
as well as co-morbidities and polypharmacy.
To understand the natural course of resolution of
acute inflammation in humans, there is need for a
model that not only resembles the inflammatory
response seen clinically in disease settings, but also
utilizes a uniform dose of inflammatory stimulus to
avoid heterogeneity. The model should also facilitate
minimally invasive sampling of inflamed tissues and
allow the appreciation of the classical signs and
symptoms of inflammation.
Acknowledging the above characteristics, we have
developed a model that combines and adapts two techni-
ques previously used separately to cause acute inflamma-
tion and harvest the inflammatory exudate. The first step
involves intradermal injection of Escherichia coli killed
by ultraviolet light (UV killed E. coli/UVKEc) into the
dermis of the forearm of healthy volunteers to trigger an
inflammatory response in an easily accessible site [8].
The second step involves raising a negative pressure suc-
tion blister over this site, to obtain the inflammatory exu-
date from the tissue [9]. Here, we present the
characterization of this model encompassing the vascular
and immunological events during onset and resolution of
acute inflammation and discuss the merits of this
approach compared to existing models of inflamma-
tion. Finally, we highlight the potential translational
use of this approach to further understand resolution
physiology and pharmacology.
Materials and methods
Ethics statement
The study was approved by UCL Institutional Ethics
Committee (Project ID: 5051/001). Written informed
consent was taken from all the volunteers. All proce-
dures were in accordance with the Helsinki Declara-
tion of 1975, as revised in 1983.
Volunteers
Characterisation study. Twenty four young (18–50
years) healthy, non-smoking male volunteers were
recruited. Volunteer exclusion criteria included any his-
tory of chronic inflammatory disease, allergies, recent
illness (<1 month), vaccination within the last 3
months, regular medication, or any medication in the
preceding week. During the study period, volunteers
were asked to refrain from alcohol and heavy exercise.
Naproxen study. Three young healthy non-smoking
male volunteers were recruited for this study arm.
Enteric-coated naproxen 500 mg was given twice
daily for 3 days prior to UVKEc injection. In addi-
tion to the exclusion criteria mentioned above, volun-
teers with history of hypersensitivity to non-steroidal
anti-inflammatory drugs (NSAIDs) or gastrointestinal
ulceration were excluded from this study arm.
Ultraviolet light killed E. coli (UVKEc): preparation
and injection
UV killed E. coli (Strain: NCTC 10418, Source: Public
Health England, UK) were prepared as described previ-
ously [8]. Briefly, E. coli were grown overnight in
Luria Broth (Sigma) at 378C. The next morning the
bacteria were washed twice in sterile PBS (2500 g, 20
min, 48C) and resuspended in a sterile petri dish. Bac-
teria were then killed by exposure to an ultraviolet light
(UV) source (302 nm, ChemiDoc, trans-UV mode;
Bio-Rad laboratories) for 60 min and then washed
again in sterile saline. Bacterial counts were determined
by optical density (OD6005 0.365 equates to 10
8 E.
coli/ml) [10]. UVKEc were resuspended in a volume
of sterile saline to obtain the count of 1.5 3 108/ml,
aliquoted into sterile eppendorf tubes and then frozen
at 2808C until used for injections. Non-viability of
final sample was confirmed by UCLH (University Col-
lege London Hospitals, UK) Microbiology department.
Intradermal injection of UVKEc
After disinfecting and shaving the skin, 1.5 3 107
UVKEc in 100 ll saline were injected intradermally
into a marked site on the volar aspect of each forearm.
To characterize the different phases of acute inflamma-
tion, each forearm was allotted to one of the predefined
time-points namely 4, 8, 14, 24, 48 or 72 hours (h).
Thus inflammation was allowed to progress for the
duration of the time-point after which a suction blister
was raised over the marked injection site, and then
aspirated immediately. In summary, volunteer had two
injection sites, one on each forearm, and contributed to
two time points. On a separate group of volunteers,
blister was raised on the na€ıve skin and treated as the
baseline time point. Study time-points were discussed
with volunteers before consenting (Figure 1A).
Laser Doppler imaging
Laser Doppler Imager (moor LDI-HIR, Moor Instru-
ments Ltd, Axminster, Devon, UK) was used to
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quantify the blood flow at the site of inflammation.
At predefined time points after injection of UVKEc,
the forearm was placed under the scanner at a fixed
distance to scan a fixed area. The scanner emits a
laser beam, a portion of which is scattered by red
blood cells present at the inflamed area. The scatter-
ing causes a change in frequency of the reflected
light which is then detected by a photo detector.
The velocity and concentration of red blood cells at
the site directly affect the Doppler frequency shifts
and account for the signal strength measured in arbi-
trary perfusion units. The data was analysed by
moorLDI software (Version 5) and displayed as col-
our coded images showing different blood flow lev-
els over the scanned area. The total blood flow
(measured in perfusion units) was calculated as
product of number of valid pixels above background
signal (Cut-off5 300 perfusion units) and the mean
blood flow signal over the valid pixels [11,12]
(Figure 1B).
Induction of suction blister
To obtain the inflammatory exudate from the site of
inflammation, a 10 mm diameter suction blister was
induced directly over the site of injection. This pro-
cedure is a modified version of the procedure
described previously [9]. Briefly, a suction blister
was raised by placing a suction blister chamber con-
nected by tubing to a negative pressure instrument
(NP-4, Electronic diversities Ltd., MD, USA). The
chamber was made of three parts: an aluminium plate
with 10 mm aperture, a nylon cup, and a transparent
glass lid, all secured by a detachable air tight seal.
The suction chamber was placed on the forearm with
the 10 mm aperture centred over the marked injec-
tion site. After securely strapping the suction cham-
ber on to the forearm, the negative pressure was
applied gradually from 2 to 6–7 inches of Mercury
(Hg) until a single uniloculated blister covering the
surface area within the aperture was formed. The
pressure was brought down gradually to baseline
Figure 1. Study protocol. Acute inflammation was triggered in the ventral aspect of the forearm of healthy volunteers by the intra-
dermal injection of 1.5 x 107 UV-killed E. coli (UVKEc) suspended in 100 ll of sterile saline (A). At pre-defined time-points after
injection, the inflamed site was scanned by a laser Doppler imager to assess blood flow (B). Subsequently, a suction chamber con-
nected to a negative pressure instrument was placed over the injection site to raise a 10 mm blister to acquire the inflammatory
exudate present at the site (C). When the blister was completely formed, its roof was pierced using a sterile needle and the contents
were aspirated (D).
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after the blister was completely formed. The suction
blister induction process took 1.5–2 h (Figure 1C).
Blister exudate aspiration
The suction blister was aspirated immediately after
formation to collect the inflammatory exudate. To
aspirate the exudate, the blister roof was pierced
along its lateral border using a 26.5 gauge needle.
The exudate was then gently pushed out onto the
skin by rolling a 1 ml syringe over the blister roof
and was simultaneously aspirated using a 200 ll pip-
ette tip. The exudate was collected into a well of a
96 well V-bottom plate containing 50 ll of 3%
sodium citrate (Sigma) in PBS (Gibco). The plate
was then centrifuged at 1000 g for 5 min at 48C to
separate the cells from the supernatant. After centrif-
ugation, the resulting cell pellet was resuspended in
Figure 2. Assessment of vascular response at the site of UVKEc-triggered resolving acute inflammation. Acute inflammation was
triggered in the ventral aspect of forearm of healthy volunteers by the intradermal injection of 1.5 x 107 UV-killed E. coli (UVKEc)
suspended in 100 ll of sterile saline. Vascular response at the site was assessed by laser Doppler imager (moorLDI-HIR) which cap-
tured the camera images (A) and also generated the flux images (B). Representative flux images at baseline, 4, 24, 48 and 72 h are
shown here. Flux images were analysed by moorLDI software to quantify total blood flow. Total blood flow, measured in perfusion
units, is shown in panel C. Data are expressed as individual values with median; n5 6 at each time point.
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Figure 3. (Legend on following page.)
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200 ll of ACK lysis buffer (Lonza) to lyse the red
blood cells (RBC). The RBC depleted cell pellet was
resuspended in 100 ll of cell staining buffer (PBS
with 5% FCS (Gibco)1 0.1% sodium azide] and the
cell count was obtained using a manual haemocytom-
eter. The supernatant was weighed to estimate the
blister fluid volume, split into 30 ll aliquots and then
stored at 2808C. The blister area was then cleaned
using 0.5% Cetrimide spray (Savlon) and covered
with a protective dressing pad (9 3 10 cm, Mepore)
[13].
Peripheral blood analysis
Peripheral blood was collected by venepuncture from
the medial cubital vein using an aseptic technique.
Blood was collected at baseline, 4, 24, 48 and 72 h
after UVKEc intradermal injection into EDTA and
heparin anti-coagulated vacutainers (BD). For full
blood counts, EDTA anti-coagulated blood was sent
to an external pathology lab (The Doctor’s Labora-
tory, Whitfield Street, London, UK). Heparin anti-
coagulated blood was centrifuged at 2500 g, 10 min,
room temperature to separate plasma. Plasma was ali-
quoted and stored at 2808C until analysed for
cytokines.
Flow cytometry
Leucocyte subpopulations in the blister fluid were
identified by poly-chromatic flow cytometry. For
cell surface marker staining, blister cells in 100 ll
of cell staining buffer (PBS with 5% FCS1 0.1%
sodium azide) were incubated with an antibody
cocktail described in supplementary material, Table
S1. Stained samples were washed in cell wash
buffer (PBS with 1% FCS1 2 mM EDTA) at 1000 g
for 5 min, 48C. Cells were then fixed in an equal
volume of 1% paraformaldehyde and stored in the
dark at 48C and analysed within 4 h on BD LSR
FortessaTM flow cytometer. Flow cytometry data
was analysed by Flowjo software (Treestar Inc.)
Multiplex ELISA
The human cytokine 30-plex kit was purchased from
Meso Scale Delivery (MSD, MD, USA). Each kit
consists of three 10-plex panels – Proinflammatory
Panel 1, Cytokine Panel 1 and Chemokine Panel 1.
The supernatant from blister exudate or the plasma
was diluted in appropriate assay diluent and the assay
was performed as per manufacturer’s instructions.
All assay components were supplied by the
manufacturer.
Statistical analysis
All data are expressed on a logarithmic scale as indi-
vidual values with medians, apart from cell propor-
tions which are expressed as median percentages.
Data from the naproxen study arm are expressed as
median with interquartile range and analysed by the
Mann-Whitney U-test. A p value <0.05 was taken as
the threshold for significance. Prism 6 (GraphPad
Software) was used for statistical analysis.
Results
Intradermal injection of UV killed E. coli (UVKEc)
triggers a clinically discernible and self-resolving
acute inflammatory response
Within 4 h of UVKEc injection, the injection site
became red; this increased in size until 24 h and then
faded by 72 h (Figure 2A). To quantify this vascular
response objectively, the site was scanned by a laser
Doppler imager. Figure 2B shows the representative
laser Doppler images. Figure 2C shows the total
blood blow in perfusion units at each time point,
indicating that blood flow plateaued from 4 h until
24 h, followed by a decline at 48 h before returning
to baseline levels by 72 h.
Cellular composition of the inflammatory exudate
at the site of UVKEc-triggered resolving acute
inflammation
To interrogate the cellular and soluble mediator pro-
file during different phases of the inflammatory
response, inflammatory exudate was obtained from
the site by raising a suction blister over it. Inflamma-
tory exudate was centrifuged to separate cells from
Figure 3. Cellular profile at site of UVKEc-triggered resolving acute inflammation. A suction blister was raised over the inflamed
site by negative pressure to collect the inflammatory exudate. Exudate was centrifuged to separate cells from the supernatant con-
taining soluble mediators. Panel A shows total white blood cells, counted manually by haemocytometer, suction blister exudate vol-
ume and total cell count per ml of exudate acquired. Panel B shows the relative proportion of neutrophils, monocytes/macrophages,
CD41 and CD81 T lymphocytes, CD561 NK cells and CD1c1 dendritic cells calculated at each time point, using the gating strategy
illustrated in Figure 4. Panel C shows cell count/ml of the above cell populations at different time points. Data are expressed as indi-
vidual values with median; n5 6 at each time point. ND 5 not detectable.
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soluble mediators. Figure 3A displays the temporal
profile of total white blood cells, which peaked at
4 h and declined progressively up to 72 h post injec-
tion. It also shows the volume of inflammatory exu-
date acquired at each time point and the cell count
adjusted for exudate volume, expressed as cells/ml.
Subpopulations of blister leucocytes were charac-
terized by polychromatic flow cytometry using a
Figure 4. Polychromatic flow cytometric gating strategy to identify subtypes of immune cells at the site of UVKEc-triggered
resolving acute inflammation. Inflammatory exudate obtained using negative pressure suction chamber was centrifuged to pellet
cells, which were then incubated with a fluorochrome-tagged antibody cocktail (supplementary material, Table S1). Stained cells
were acquired on BD LSR FortessaTM and analysed by Flowjo software. The gating strategy employed to identify neutrophils, mono-
cytes/macrophages, CD41 and CD81 T lymphocytes, CD561 NK cells and CD1c1 dendritic cells is illustrated. Representative plots
from the 14 h time point (when all subtypes of immune cells are adequately present) are shown.
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gating strategy described previously [14]. Figure 4
shows the typical gating strategy employed here to
discern the cell types at different time points (a rep-
resentative sample from the 14 h time point when all
immune cell subtypes are adequately present is
shown). After exclusion of debris (Figure 4i), cells of
haematopoetic origin (CD451) were separated (Fig-
ure 4ii) followed by doublet exclusion (Figure 4iii).
CD451 single cell events were probed for CD3
expression and were further separated into CD41 and
CD81 T cells (Figure 4iv, vi). The remaining
CD451/CD3- compartment (Figure 4iv; B cells were
present in very low numbers in the blister at all the
time-points) was probed for CD561 NK cells (Figure
4v). The CD56- myeloid cell population was then
investigated for HLA-DR and CD16 to separate
mononuclear cells and granulocytes (Figure 4vii).
The HLA-DR1 population was further probed for
CD14 and CD16, revealing two distinct populations
of HLA-DR1/CD141 monocytes/macrophages and
HLA-DR1/CD14-/CD16- cells (Figure 4viii); a major
proportion of which comprised CD1c1 dendritic cells
(Figure 4ix). The HLA-DR- gate comprised mainly
CD1611 neutrophils (Figure 4vii). Figure 3B shows
the relative proportions of cells characterized above
and Figure 3C shows the count/ml of these cells in
blister exudate at different phases of inflammation.
On studying the temporal profiles of the individual
cell types (expressed as count/ml of inflammatory
exudate), it was evident that the influx of neutrophils
at the site peaked at 4 h, which then gradually
cleared, reducing by >90% at 48 h. A closer look at
monocyte/macrophage kinetics suggested a biphasic
profile; a first peak was observed at 8 h and then a
rise at 24 h (Figure 3C). Further analysis of cell sur-
face markers on these cells revealed an increase in
the expression of CD16 as well as CD163 and CCR7
from 24 to 48 h (supplementary material, Figure S1).
In addition to the distinct population of HLA-DR1/
CD1c1 cells peaking at 24 h, CD1c expression was
found to increase on these monocytes/macrophages
from 48 h onwards (supplementary material, Figure
S1).
Analysis of lymphocyte populations showed the
presence of CD41 and CD81 T cells in the na€ıve
skin. The number of these cells increased with
the onset of inflammation, but unlike the myeloid
cells (neutrophils, monocytes/macrophages and
dendritic cells) the number of these lymphoid
cells (including CD561 NK cells) remained
Figure 5. Cytokine and chemokine profile at the site of UVKEc-triggered resolving acute inflammation. Inflammatory exudate
obtained using negative pressure suction chamber was centrifuged to separate cells from the supernatant containing soluble media-
tors. Cytokines and chemokines in the supernatant were probed by a multiplex ELISA. Data are expressed as individual values with
median; n5 6 at each time point.
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constant after the resolution of the clinical signs
of inflammation. At 48 and 72 h, lymphocytes
were therefore the major cell type present in the
inflammatory exudate.
To ensure that the systemic inflammatory response
to UVKEc injection was minimal and self-resolving,
full blood counts (FBCs) were obtained from periph-
eral blood. At 4 h, a mild increase in total white
blood cells and neutrophils above the reference range
(marked as dotted lines on the graph) was observed.
By 24 h, total white blood cell and neutrophil counts
returned to baseline levels. Monocyte and lympho-
cyte counts remained within the reference ranges
(supplementary material, Figure S4).
Cytokine and chemokine profile at the site of
UVKEc-triggered resolving acute inflammation
The cell-free inflammatory exudate was analysed for
chemokines and cytokines and studied alongside the
vascular and cellular response described above. Fig-
ure 5 shows that, at 4 h, the classical pro-
inflammatory cytokines TNF-a, IL-8, IL-1b were at
their highest concentrations alongside the anti-
inflammatory cytokine IL-10. IFN-c peaked at 8 h,
whilst IL-6 plateaued from 4 h until 24 h. By 72 h,
concurrent with the vascular and cellular resolution,
the levels of these cytokines had declined to baseline
levels. Additional cytokines measured during the
multiplex ELISA are shown in supplementary
Figure 6. Validation of the anti-inflammatory effect of naproxen using the UVKEc-triggered resolving acute inflammation model.
Volunteers were given naproxen 500 mg twice daily for 3 days prior to the UVKEc injection. Four hours after the injection, the site
was scanned by laser Doppler imager to quantify total blood flow and then a suction blister was raised to collect the inflammatory
exudate. Panel A shows the total blood flow at 4 h in the control and naproxen study arms. Representative laser Doppler flux images
are also shown. Panel B shows the neutrophil count/ml at 4 h between control and naproxen study arm. Data are expressed as
median with interquartile range; n5 6 for control and n5 3 for naproxen study arm, *p< 0.05.
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material, Figures S2 and S3. Cytokines were also
measured in the plasma but their levels were either
very low or did not exhibit the temporal profile
observed in blister exudates. (supplementary material,
Figure S5).
Validation of the UVKEc-triggered resolving
inflammation model for testing an anti-
inflammatory effect
In a separate study arm, three volunteers were given
naproxen 500 mg twice daily for the 3 days prior to
UVKEc injection, after which a blister was raised at
4 h. At 4 h, naproxen significantly reduced the total
blood flow over the injection site as well as the neu-
trophil count in the blister exudate (Figure 6).
Discussion
The intradermal injection of UVKEc elicits a self-
resolving inflammatory response that allows for the
simultaneous assessment of vascular response, cellu-
lar migration and soluble mediator profiles during
onset and resolution phases of acute inflammation in
humans.
The onset phase was evident within 4 h and was
characterized by an increase in blood blow, maximal
number of immune cells comprising mainly neutro-
phils, and the highest concentrations of classical pro-
inflammatory cytokines. The vascular response pla-
teaued from 4 h until 24 h and started to resolve
thereafter, approaching baseline levels by 72 h. In
contrast, cellular resolution, classically defined by
reduction of neutrophil numbers [15], ensued gradu-
ally from 4 h, with >90% of neutrophils cleared by
48 h. Unlike neutrophils, monocytes/macrophages
showed a biphasic profile. At 8 h, monocytes/macro-
phages resembled classical phenotype (CD14hi
CD16-), followed at 24 h by the presence of a popu-
lation resembling the intermediate phenotype
(CD14hiCD161) expressing resolution phase related
markers: CD163 [16,17] and CCR7 [18,19]. In line
with cellular resolution, the pro-inflammatory cyto-
kines declined gradually, reaching near baseline lev-
els by 48 h. At 72 h, blood flow reverted back to
normal, however the inflammatory exudate still con-
tained cells of the adaptive immune system, namely
CD4, CD8 and CD56 lymphocytes. These findings
are consistent with our existing knowledge of the
acute inflammatory response seen in humans and are
also reminiscent of events characterizing cellular
resolution in mouse models [20,21]. In addition, the
expected suppression of the onset phase, at a clinical
and cellular level, by the anti-inflammatory drug nap-
roxen supports the use of this model for pharmaco-
logical drug testing.
When compared to other in vivo models of acute
inflammation in humans, this model offers distinct
advantages. Firstly, it generates a robust, clinically
evident inflammatory response followed by resolution.
This is attributable to our choice of inflammatory
stimulus, and its site of inoculation in the dermal con-
nective tissue. Other skin models of inflammation trig-
gered by tissue injury either using a chemical, eg
Cantharidin [22] or mechanical trauma eg dermal
abrasion [23] or tape stripping [24] generate an
inflammatory response evidenced by cell migration
and detection of pro-inflammatory mediators, but are
suitable only to study the onset phase. Studying reso-
lution in such tissue injury models has been inad-
equate as inflammation develops on debrided skin and
not within the connective tissue. The connective tissue
environment provides the stromal scaffold including
the vascular and lymphatic network. This facilitates
cell-cell interaction and cell migration important for
key processes leading to resolution ie efferocytosis
[25,26], vascular reverse transmigration [27] and lym-
phatic emigration [19]. Similar to skin tissue injury
models, the skin window technique, which involves
creating an artificial cavity over the denuded skin site,
only serves well to study initial cell migration due to
the absence of stromal scaffold [28,29].
This model of resolving inflammation also utilizes
a minimally invasive technique of suction blister to
acquire the inflammatory exudate from the site.
Obtaining inflammatory exudate in this way provides
cells that facilitate polychromatic flow cytometry,
which allows simultaneous evaluation of multiple
immune cell markers. Furthermore, soluble mediators
can be measured in the cell-free exudate. This con-
trasts with other models of skin inflammation caused
by intradermal endotoxin injection [30], or UV radia-
tion [31,32] which utilize the relatively invasive tech-
nique of skin biopsy in order to study the
inflammatory response. The skin biopsy sample thus
obtained has been shown to provide limited informa-
tion either on individual cell populations by semi-
quantitative immunohistochemistry or on individual
cytokine measurements by Western blot.
Another commonly used model of acute inflamma-
tion involves lung lipopolysaccharide (LPS) chal-
lenge [33]. Compared to this LPS model, our
UVKEc-triggered model of resolving inflammation is
significantly less invasive and also allows interroga-
tion of more than one skin site thus permitting evalu-
ation of different phases of inflammation in the same
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person. As to the i.v. endotoxaemia model [34],
which primarily elicits the systemic inflammatory
response mimicking early sepsis, intradermal UVKEc
investigates tissue inflammation driven by the circu-
lating and the resident immune cell compartment.
Although we argue that our model of self-
resolving inflammation is well-suited to the study of
resolution of inflammation in humans, it does have
some limitations that are important to consider when
planning research studies. The robust inflammatory
response produced during onset causes a moderately
swollen and tender lesion over the forearm. In some
cases this is accompanied by minor discomfort in the
axillary region, presumably due to increased lym-
phatic flow in the axillary lymph nodes. Some volun-
teers also complained of headache and muscle ache
in the first 4-8 h, resembling a mild flu-like syn-
drome. However, in all cases the symptoms subsided
after 24 h and disappeared by 48 h. The blister
induction process in itself caused only mild discom-
fort. After blister aspiration, the site formed a scab
which left a pigmented scar. This faded considerably
within 4–6 weeks on Caucasian skin but took longer
on darker skin types.
In conclusion, intradermal injection of UVKEc
generates a rapid and robust inflammatory response
that allows investigation of immunological and vas-
cular events associated with onset and resolution
phases of inflammation in a minimally invasive way.
We propose that it is a robust translational platform
to study the mechanisms of novel anti-inflammatory
and pro-resolving drugs and simultaneously assess
their effect on the clinical signs of inflammation. In
addition, it can be used as a tool in patients with
chronic inflammatory disorders to investigate the
contribution of defective resolution to the pathogene-
sis of such conditions.
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